Apollomics (APLM) vs Fortress Biotech (FBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Fortress Biotech (FBIO) has outperformed Apollomics (APLM) over the past year, losing 30.7% versus a loss of 42.4%. Fortress Biotech is the larger company by market cap ($62.4 million vs $61.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | APLM | FBIO |
|---|---|---|
| Share price | $21.10 | $1.87 |
| Market cap | $61.51M | $62.37M |
| 1-day change | -0.00% | -2.09% |
| YTD return | +12.86% | -48.91% |
| 1-year return | -42.43% | -30.74% |
| 5-year return | — | -95.84% |
| P/E ratio (TTM) | — | 0.68 |
| EPS (TTM) | $-7.57 | $2.76 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $63.26M |
| Revenue growth (YoY) | — | +9.69% |
| Net income (latest FY) | $-53.86M | $6.82M |
| Gross margin | — | 66.92% |
| Operating margin | — | -111.00% |
| Net margin | — | 10.77% |
| 52-week high | $36.53 | $4.53 |
| 52-week low | $10.01 | $1.84 |
| Distance from 52-week high | -42.23% | -58.72% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +167.38% |
| Average volume | 15.35K | 448.52K |
| Shares outstanding | 2.91M | 33.35M |
| Employees | 14 | 78 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FBIO has outperformed APLM by 11.7 percentage points over the past year.
About Apollomics
APLM stock →Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; and APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial for cancer treatment.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
About Fortress Biotech
FBIO stock →Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 78 employees
APLM vs FBIO FAQ
Which is bigger, Apollomics or Fortress Biotech?
Fortress Biotech (FBIO) is larger, with a market capitalization of $62.37M compared with $61.51M for Apollomics (APLM).
Which stock has performed better over the past year, APLM or FBIO?
FBIO returned -30.74% over the past 12 months, compared with -42.43% for APLM (price return, excluding dividends). Past performance does not predict future results.
Are Apollomics and Fortress Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.